世界の徐放性ドラッグデリバリー市場(~2026):投与量・価格・臨床試験インサイト

◆英語タイトル:Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2026
◆商品コード:KUIK21FB011
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年7月
◆ページ数:1000
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Multi UserUSD5,100 ⇒換算¥581,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の徐放性ドラッグデリバリー市場について調査・分析を行い、イントロダクション、徐放性ドラッグデリバリーの分類、作用機序、材料ベースアプローチ、臨床パイプライン、疾患別(糖尿病、がん、心血管疾患、神経障害、感染症)分析、投与量・製剤洞察、アルツハイマー病における徐放性薬剤、パーキンソン病における徐放性薬剤、統合失調症における徐放性薬剤、慢性痛における徐放性薬剤、多発性硬化症における徐放性薬剤、2型糖尿病における徐放性薬剤、高血圧症&狭心症における徐放性薬剤、臨床試験、地域別動向、市場動向、将来見通し、競争状況などを掲載しています。
・イントロダクション
・徐放性ドラッグデリバリーの分類
・作用機序
・材料ベースアプローチ
・臨床パイプライン
・世界の徐放性ドラッグデリバリー市場:疾患別(糖尿病、がん、心血管疾患、神経障害、感染症)
・投与量・製剤洞察
・アルツハイマー病における徐放性薬剤
・パーキンソン病における徐放性薬剤
・統合失調症における徐放性薬剤
・慢性痛における徐放性薬剤
・多発性硬化症における徐放性薬剤
・2型糖尿病における徐放性薬剤
・高血圧症&狭心症における徐放性薬剤
・臨床試験
・地域別動向
・市場動向
・将来見通し
・競争状況
【レポートの概要】

“Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2026″ Report Highlights:

Global Controlled Release Drug Delivery Market: More Than US$ 70 Billion Opportunity by 2026
US and Europe Market Share 2019: > 65%
US and Europe To Double It Market Sales Opportunity by 2026
Number of Controlled Release Drug Available in Market: > 140 Drugs
Clinical Trials Insight by Company, Country, Indication and Patent: > 250 Drugs
Controlled Release Drugs Pricing, Patent and Dosage Insight
Global and Regional Trend Analysis, Future Market Opportunity Outlook
Global Controlled Drug Delivery Market Dynamics

The market established for the target patient segment focuses towards delivering drugs at a predetermined rate, systemically or locally for a specific period of time. Although the market is predominated by regular drugs but the continuous delivery of the drugs whose kinetics can be controlled is achieving a predictable growth curve. The market utilizes drug encapsulating devices which employ controlled release of the therapeutic agents ranging from days to months. The numerous advantages provided by market over traditional methods of drug delivery such as tailoring of rate of drug release, fragile drug protection and patient comfort and compliance is what changing the prescription pattern of the doctors towards controlled release drugs.

Extensions supplied to the available drug market in terms of mechanical strength, increasing demand of the patient population and novel drugs capable of achieving high drug loading are some of the factors that are considered as major driving factors for the controlled release drug delivery market. Other than the above mentioned factors, the market is coupled with reduced drug toxicity which is however estimated to boost the market growth in a short period of time.

In the last few years, increasing efforts have been delivered in order to diversify the range of the drug delivery and this has been processed by increasing the association of the researchers with the daily and unmet needs of the patient population. The availability of the controlled release drug delivery system in the market has shown a great progress towards handling the situation of the complex real world as the emergence of drugs that could not regulate the complex composition of disease was hampering with the overall growth of the drug market.

The availability of controlled release drugs in oral, injectable, nasal, topical and implantable forms for the patient population is making the market more dominant than the other available markets. The emergence of the market ended the search for the novel solutions to address the therapeutics challenges as well as has provided a great concern in the biotechnology and pharmaceutical industries. The amazing perspective lined up the way of controlled released drug market represents a more personalized and efficient delivery system in the coming years.

Although the platform that has been provided by the controlled release drug delivery market is novel but the drug delivery platform provided by market has been associated with impressive clinical pipeline. It carries the potential to treat a broad spectrum of disease such as infectious diseases, inflammatory diseases, autoimmune diseases, neurological diseases and several different types of cancer. The market is capable of offering a revolutionized treatment for the patients in order to truly modify the benefits that the patients were receiving from a long period of time.

As per report findings, it is estimated that the market is availing safe and effective pharmacotherapeutic treatment regimen for the patient population that are in an urgent need of the drug delivery system capable of transforming their treatment schedule. Although the market is associated with significant challenges for the scientists and clinicians but the availability of technological drivers will be responsible for rapid discovery of drugs related to the market. The formulation changes and safety specifications coupled with the market is estimated to encourage the people towards its consumption. The optimistic landscape of the market guarantees the complete success of the market as well as a major competition for the drugs in the near future.

【レポートの目次】

Introduction to Drug Delivery Methodology
1.1 Drug Delivery Overview
1.2 Drug Delivery System

Introduction to Controlled Drug Delivery
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery
2.3 Drug Delivery Technology
2.3.1 First Generation
2.3.2 Second Generation
2.4 Fundamentals of Controlled Delivery
2.5 Basis for Controlled Drug Delivery

Controlled Drug Delivery Classification
3.1 By Delivery Systems
3.1.1 Immediate Drug Release System
3.1.2 Modified Drug Release System
3.1.3 Delayed Release System
3.1.4 Extended Release System
3.1.5 Pulsatile Drug Release System
3.2 By Technology
3.2.1 Rate Preprogrammed Drug Delivery System
3.2.2 Activation Modulated Drug Delivery System
3.2.3 Feed Back Regulated Drug Delivery System
3.2.4 Site Targeted Drug Delivery Systems
3.3 By Routes of Delivery
3.3.1 Oral Controlled Drug Delivery System
3.3.2 Nasal Controlled Drug Delivery System
3.3.3 Transdermal Controlled Drug Delivery System
3.3.4 Ocular Controlled Drug Delivery System
3.3.5 Parenteral Controlled Drug Delivery

Controlled Drug Delivery Mechanism of Action
4.1 Diffusion Controlled
4.2 Dissolution Controlled System
4.3 Water Penetration Controlled System
4.4 Erosion Controlled System
4.5 Ion-Exchange Controlled System

Material Based Approaches for Controlled Drug Delivery
5.1 Polymers
5.2 Chronopharmaceutics
5.3 Nanoparticulate Delivery System

Global Controlled Release Drug Clinical Pipeline Overview
6.1 Phase
6.2 Country/Region
6.3 Mode of Action
6.4 Drug class
6.5 Indication

Controlled Drug Delivery by Indication
7.1 Diabetes
7.2 Cancer
7.3 Cardiovascular Diseases
7.4 Neurological Disorders
7.5 Infections

Controlled Delivery Drug Dosage and Formulation Insight
8.1 Enteral Dosage Formulations
8.1.1 Solid Dosage Forms
8.1.2 Liquid Dosage Forms
8.1.3 Inhalation Dosage Forms
8.2 Parenteral Dosage Forms
8.2.1 Injectable Dosage Forms
8.2.2 Implantable Device
8.3 General Mechanisms of Drug Release

Controlled Release Drugs for Alzheimer’s Disease – Pricing, Patent and Dosage Insight
9.1 Namzaric (Extended-Release)
9.2 Namenda XR (Extended – Release)
9.3 Razadyne ER (Extended – Release)

Controlled Release Drugs for Parkinson’s Disease – Pricing, Patent and Dosage Insight
10.1 Gocovri (Extended- Release)
10.2 Osmolex ER (Extended – Release)

Controlled Release Drugs for Schizophrenia – Pricing, Patent and Dosage Insight
11.1 Perseris (Extended – Release)
11.2 Invega (Extended – Release)
11.3 Invega Sustenna/Invega Trinza (Extended – Release)
11.4 Seroquel XR (Extended – Release)
11.5 Abilify Maintena (Extended – Release)
11.6 Aristada (Extended – Release)

Controlled Release Drugs for Chronic Pain – Pricing, Patent and Dosage Insight
12.1 Zohydro ER (Extended – Release)
12.2 Hysingla ER (Extended – Release)
12.3 Nucynta ER (Extended – Release)
12.4 Kadian (Extended – Release)
12.5 Arymo ER (Extended – Release)
12.6 Xtampza ER (Extended – Release)
12.7 MS Contin (Extended – Release)
12.8 Embeda (Extended – Release)

Controlled Release Drugs for Multiple Sclerosis – Pricing, Patent and Dosage Insight
13.1 Ampyra (Extended – Release)
13.2 Tecfidera (Delayed – Release)
13.3 Rayos (Delayed – Release)
13.4 Vumerity (Delayed – Release)

Controlled Release Drugs for Diabetes Mellitus Type II – Pricing, Patent and Dosage Insight
14.1 Glumetza (Extended – Release)
14.2 Glucotrol XL (Extended – Release)
14.3 Fortamet (Extended – Release)
14.4 Glucophage XR (Extended – Release)
14.5 Bydureon (Extended – Release)

Controlled Release Drugs for Hypertension and Angina Pectoris – Pricing, Patent and Dosage Insight
15.1 Procardia XL (Extended – Release)
15.2 Toprol XL (Extended – Release)
15.3 Adalat CC (Extended – Release)
15.4 Verelan PM (Extended – Release)
15.5 Plendil (Extended – Release)
15.6 Cardizem LA (Extended – Release)

Global Controlled Drug Clinical Trials Insight By Company, Indication and Phase
16.1 Unknown
16.2 Research
16.3 Preclinical
16.4 Clinical
16.5 Phase-I
16.6 Phase-I/II
16.7 Phase-II
16.8 Phase-II/III
16.9 Phase-III
16.10 Preregistration
16.11 Registered

Marketed Controlled Drug Clinical Insight By Company and Indication

Global Controlled Drug Market Overview and Recent Trends at Regional Level
18.1 US
18.2 Europe
18.3 Japan

Global Controlled Drug Delivery Market Dynamics
19.1 Market Drivers
19.2 Challenges to be Resolved

Global Controlled Drug Delivery Market Future Outlook

Competitive Landscape
21.1 Allergan
21.2 Amylin Pharmaceuticals
21.3 AstraZeneca
21.4 BioAlliance Pharma
21.5 Biogen
21.6 Collegium Pharmaceutical
21.7 Controlled Therapeutics (Ferring Pharmaceuticals)
21.8 Cosmo Pharmaceuticals
21.9 Egalet
21.10 Elan Corporation
21.11 Encore Therapeutics
21.12 Flamel Technologies
21.13 GlaxoSmithKline
21.14 Heron Therapeutics
21.15 iCeutica
21.16 Mithra Pharmaceuticals
21.17 Neurim Pharmaceuticals
21.18 Novartis
21.19 Orexigen Therapeutics
21.20 Otsuka Pharmaceutical
21.21 Pfizer
21.22 Purdue Pharma
21.23 Syntex Pharmaceuticals International
21.24 Takeda
21.25 Zealand Pharma



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の徐放性ドラッグデリバリー市場(~2026):投与量・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆